• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Pharma Fever Grips Dealmakers Despite M&A Spike and a Frenzy IPO Year

Share:

January 22, 2022

Several high-profile investment bankers opted to stay out of the dealmaking business to join more strategic roles in the last 12-18 months, despite record M&A volumes and a frenzy IPO year that resulted in record fee collection for dealmakers.

The move was more evident in the pharma sector, where the pandemic opened up a plethora of consolidation and fundraising opportunities.

More than a dozen top bankers moved to strategic and M&A roles in pharmaceutical companies, spearheading mergers and acquisitions as well as fundraising plans. They included Nitin Tandon, who joined as head of business development, Asia Pacific, at Johnson & Johnson from Credit Suisse. Moelis & Co’s Ashish Mukkirwar joined Glenmark to head its strategy and M&A team, while very recently, a prolific pharmaceuticals banker at O3 Capital, Gawir Baig, moved to play the role of a chief financial officer at Anthem Biosciences, a drug discovery platform in which True North recently invested. V Krishnakumar was another high-profile move; he left EY after a long tenure of consistent healthcare M&A closures to join Eris Life Sciences as its chief operating officer.

“Pharma is seeing a lot of M&A and fundraise activity, leading to demand I-banking talent in these companies,” said Anshul Lodha, regional director at recruitment firm Page Group. “I-bankers are also keen to switch to the corporate side to get more well-rounded exposure than just fundraising. They get actively involved in the operational side of the business with corporates which is a great role enhancement for them,” Lodha said.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Read more here

Source: Economictimes

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
  • Turning to Digital Technology to Improve Access to Mental Health CareTurning to Digital Technology to Improve Access to Mental Health Care
  • French Diagnostic Software Developer Primaa Raises €2m in Seed FundingFrench Diagnostic Software Developer Primaa Raises €2m in Seed Funding
  • Illumina to Acquire Pacific Biosciences for Approximately $1.2 BillionIllumina to Acquire Pacific Biosciences for Approximately $1.2 Billion
  • Well Health Nabs $45M to Expand Intelligent Communications HubWell Health Nabs $45M to Expand Intelligent Communications Hub
  • Redpin Therapeutics Secures Initial Closing of $15.5 Million in Series A FinancingRedpin Therapeutics Secures Initial Closing of $15.5 Million in Series A Financing
  • Eyeing Healthcare Providers, Microsoft Updates Its Team Coordination Platform with Interoperable EHR Support, Messaging FeaturesEyeing Healthcare Providers, Microsoft Updates Its Team Coordination Platform with Interoperable EHR Support, Messaging Features
  • Gnosis By Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharmaGnosis By Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma

Trending This Week

  • In the wake of Dobbs, women’s health is ‘Ripe for investment’
  • New tools and acquisitions from OptumRx, ScionHealth.
  • Market Skeptical Following Sen. Warren’s Antitrust Allegations
  • Rogers, Shaw tick lower amid a report that Industry Minister in no hurry to Ok deal
  • ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, furthering its Ambition to Become the Global Leader in Regenerative Therapies
  • LGM Pharma Acquires Pharmaceutical Development and Manufacturing Unit of Nexgen Pharma

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications